Vanguard Group Reports 0% Stake in Insmed Inc Due to Internal Realignment
INSMED Inc
Subscribe to track INSM
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Vanguard Group Reports 0% Stake in Insmed Inc Due to Internal Realignment
Company: Insmed Inc (INSMED Inc) Form: SCHEDULE 13G/A | Filed: 2026/03/27 Significance: Low (Administrative)
Investor: The Vanguard Group Role: Institutional Investor
Filing Details: • Shares Owned: 0 • Percent of Class: 0% • Reason: Internal Realignment
Key Insight: Vanguard Group reports 0 shares beneficially owned following an internal realignment on Jan 12, 2026. Subsidiaries will now report beneficial ownership separately, meaning this is a change in reporting structure rather than a liquidation of the position.
Market Context: Insmed Inc has a market cap of $29.32B. This filing represents a technical administrative change for one of the world's largest asset managers.
Comprehensive Analysis
SEC Filing Analysis: Insmed Inc
Executive Summary
- Trading Significance: Low (Administrative)
- Key Takeaway: The Vanguard Group reports 0% ownership due to an internal corporate realignment, not necessarily a market sale.
- Market Impact: Neutral; the underlying assets are likely still held by Vanguard subsidiaries which will report separately.
Company Information
| Field | Value |
|---|---|
| Company | Insmed Inc |
| CIK | 0001104506 |
| Industry | Pharmaceutical Preparations |
| Market Cap | $29.32 Billion |
Insider Information
| Field | Value |
|---|---|
| Name | The Vanguard Group |
| CIK | 0000102909 |
| Type | Institutional Investor |
| Location | Malvern, PA |
Transaction Details
| Field | Value |
|---|---|
| Form Type | SCHEDULE 13G/A |
| Event Date | 2026/03/13 |
| Shares Owned After | 0 |
| Percent of Class | 0% |
| Voting Power | 0 |
Financial Impact Assessment
Transaction Materiality
- Reported Ownership: 0 shares (0.00% of outstanding)
- Previous Stake: Not specified in this amendment (Amendment 11 implies long-standing history).
- Materiality Assessment: Low. While a reduction to 0% is typically significant, the explanatory notes clarify this is technical.
Impact Evaluation
- Context: The filing includes a specific footnote stating: "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment... certain subsidiaries... will report beneficial ownership separately."
- Dilution/Concentration: No impact on dilution. The concentration of ownership likely remains with Vanguard-affiliated entities, just distributed across different reporting keys.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The filing explicitly attributes the change to an internal realignment and regulatory release compliance (SEC Release No. 34-39538). It does not indicate a bearish sentiment or a liquidation of the position.
Volume & Sentiment
- Expected Volume Impact: Negligible.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Regulatory Nuance: The filer cites SEC Release No. 34-39538, allowing subsidiaries to report as distinct beneficial owners. This decentralizes the reporting of Vanguard's massive holdings.
- Timing: The realignment occurred Jan 12, 2026, with the event date triggering this filing on March 13, 2026.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.